Jackson, C. M., Choi, J. & Lim, M. Mechanisms of immunotherapy resistance: classes from glioblastoma. Nat. Immunol. 20, 1100–1109 (2019).
Haar, C. P. et al. Drug resistance in glioblastoma: a mini evaluation. Neurochem. Res. 37, 1192–1200 (2012).
Meng, X. et al. Twin functionalized brain-targeting nanoinhibitors restrain temozolomide-resistant glioma through attenuating EGFR and MET signaling pathways. Nat. Commun. 11, 594 (2020).
Stupp, R. et al. Results of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised section III examine: 5-year evaluation of the EORTC-NCIC trial. Lancet Oncol. 10, 459–466 (2009).
Klemm, F. et al. Interrogation of the microenvironmental panorama in mind tumors reveals disease-specific alterations of immune cells. Cell 181, 1643–1660.e1617 (2020).
Meng, X. et al. DNA injury restore alterations modulate M2 polarization of microglia to rework the tumor microenvironment through the p53-mediated MDK expression in glioma. eBioMedicine 41, 185–199 (2019).
Kaina, B. & Christmann, M. DNA restore in customized mind most cancers remedy with temozolomide and nitrosoureas. DNA Restore 78, 128–141 (2019).
Li, Z. et al. Glioblastoma cell-derived lncRNA-containing exosomes induce microglia to supply complement C5, selling chemotherapy resistance. Most cancers Immunol. Res. 9, 1383–1399 (2021).
Wang, Y. et al. Nanoparticle-mediated convection-enhanced supply of a DNA intercalator to gliomas circumvents temozolomide resistance. Nat. Biomed. Eng. 5, 1048–1058 (2021).
Chen, G. et al. A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complicated for in vivo genome enhancing. Nat. Nanotechnol. 14, 974–980 (2019).
Zou, Y. et al. Single siRNA nanocapsules for efficient siRNA mind supply and glioblastoma therapy. Adv. Mater. 32, 2000416 (2020).
Liu, Q. et al. Multistage supply nanoparticle facilitates environment friendly CRISPR/dCas9 activation and tumor development suppression in vivo. Adv. Sci. 6, 1801423 (2019).
Liu, Q. et al. NanoRNP overcomes tumor heterogeneity in most cancers therapy. Nano Lett. 19, 7662–7672 (2019).
Xu, J. et al. Exact concentrating on of POLR2A as a therapeutic technique for human triple unfavorable breast most cancers. Nat. Nanotechnol. 14, 388–397 (2019).
Gilleron, J. et al. Picture-based evaluation of lipid nanoparticle–mediated siRNA supply, intracellular trafficking and endosomal escape. Nat. Biotechnol. 31, 638–646 (2013).
Solar, Q., Zhou, Z., Qiu, N. & Shen, Y. Rational design of most cancers nanomedicine: nanoproperty integration and synchronization. Adv. Mater. 29, 1606628 (2017).
Solar, Q. et al. Integration of nanoassembly capabilities for an efficient supply cascade for most cancers medication. Adv. Mater. 26, 7615–7621 (2014).
Donahue, N. D., Acar, H. & Wilhelm, S. Ideas of nanoparticle mobile uptake, intracellular trafficking, and kinetics in nanomedicine. Adv. Drug Deliv. Rev. 143, 68–96 (2019).
Zhao, Y. et al. Nanomechanical motion opens endo-lysosomal compartments. Nat. Commun. 14, 6645 (2023).
Obermeier, B., Daneman, R. & Ransohoff, R. M. Growth, upkeep and disruption of the blood-brain barrier. Nat. Med. 19, 1584–1596 (2013).
Zhao, Y. et al. Neuroprotective nanoscavenger induces coaggregation of β-amyloid and facilitates its clearance in Alzheimer’s illness mind. CCS Chem. 3, 2316–2330 (2021).
Rose, D. A. et al. Self-immolative hydroxybenzylamine linkers for traceless protein modification. J. Am. Chem. Soc. 144, 6050–6058 (2022).
Maier, Okay. & Wagner, E. Acid-labile traceless click on linker for protein transduction. J. Am. Chem. Soc. 134, 10169–10173 (2012).
Bernardes, G. J., Steiner, M., Hartmann, I., Neri, D. & Casi, G. Web site-specific chemical modification of antibody fragments utilizing traceless cleavable linkers. Nat. Protoc. 8, 2079–2089 (2013).
Wang, M., Solar, S., Neufeld, C. I., Perez‐Ramirez, B. & Xu, Q. Reactive oxygen species‐responsive protein modification and its intracellular supply for focused most cancers remedy. Angew. Chem. 126, 13662–13666 (2014).
Zhang, Z. et al. Twin‐locking nanoparticles disrupt the PD‐1/PD‐L1 pathway for environment friendly most cancers immunotherapy. Adv. Mater. 31, 1905751 (2019).
Jiang, Y., Yang, W., Zhang, J., Meng, F. & Zhong, Z. Protein toxin chaperoned by LRP‐1‐focused virus‐mimicking vesicles induces excessive‐effectivity glioblastoma remedy in vivo. Adv. Mater. 30, 1800316 (2018).
Kim, B. et al. Securing the payload, discovering the cell, and avoiding the endosome: peptide‐focused, fusogenic porous silicon nanoparticles for supply of siRNA. Adv. Mater. 31, 1902952 (2019).
Kim, H.-R. et al. Fusogenic liposomes encapsulating mitochondria as a promising supply system for osteoarthritis remedy. Biomaterials 302, 122350 (2023).
Zhao, X. et al. Tumor cell floor modification with immuno-amplified nanoparticles to reinforce most cancers immunotherapy. Mater. At present Chem. 27, 101303 (2023).
Kube, S. et al. Fusogenic liposomes as nanocarriers for the supply of intracellular proteins. Langmuir 33, 1051–1059 (2017).
Chou, L. Y., Ming, Okay. & Chan, W. C. Methods for the intracellular supply of nanoparticles. Chem. Soc. Rev. 40, 233–245 (2011).
Zheng, C. et al. Membrane‐fusion‐mediated multiplex engineering of tumor cell floor glycans for enhanced NK cell remedy. Adv. Mater. 35, 2206989 (2023).
He, Y. et al. Monensin enhanced era of extracellular vesicles as transfersomes for selling tumor penetration of pyropheophorbide-a from fusogenic liposome. Nano Lett. 22, 1415–1424 (2022).
Han, H. et al. Focused fusogenic liposomes for efficient tumor supply and penetration of lipophilic cargoes. ACS Biomater. Sci. Eng. 9, 1919–1927 (2023).
Zheng, C. et al. Anti-phagocytosis-blocking repolarization-resistant membrane-fusogenic liposome (ARMFUL) for adoptive cell immunotherapy. Sci. Adv. 9, eadh2413 (2023).
Zhang, P. et al. A multistage cooperative nanoplatform allows intracellular co‐supply of proteins and chemotherapeutics for most cancers remedy. Adv. Mater. 32, 2000013 (2020).
Zheng, C. et al. In situ modification of the tumor cell floor with immunomodulating nanoparticles for efficient suppression of tumor development in mice. Adv. Mater. 31, 1902542 (2019).
Zhao, Y. et al. Bi-specific macrophage nano-engager for most cancers immunotherapy. Nano At present 41, 101313 (2021).
Lu, Y. et al. Microenvironment reworking micelles for Alzheimer’s illness remedy by early modulation of activated microglia. Adv. Sci. 6, 1801586 (2019).
de Gracia Lux, C. et al. Biocompatible polymeric nanoparticles degrade and launch cargo in response to biologically related ranges of hydrogen peroxide. J. Am. Chem. Soc. 134, 15758–15764 (2012).
Udenfriend, S. et al. Fluorescamine: a reagent for assay of amino acids, peptides, proteins, and first amines within the picomole vary. Science 178, 871–872 (1972).
Zhao, Y. et al. Stapled liposomes improve cross‐priming of radio‐immunotherapy. Adv. Mater. 34, 2107161 (2022).
Zhao, Y. et al. Polymer‐strengthened liposomes amplify immunogenic cell demise‐related antitumor immunity for photodynamic‐immunotherapy. Adv. Funct. Mater. 32, 2209711 (2022).
Manders, E. M., Verbeek, F. & Aten, J. Measurement of co‐localization of objects in twin‐color confocal pictures. J. Microsc. 169, 375–382 (1993).
Barroso, S. I. & Aguilera, A. Detection of DNA double-strand breaks by gamma-H2AX immunodetection. Strategies Mol. Biol. 2153, 1–8 (2021).
Taha, E. A., Lee, J. & Hotta, A. Supply of CRISPR-Cas instruments for in vivo genome enhancing remedy: developments and challenges. J. Management. Launch 342, 345–361 (2022).